Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer

Trial Profile

Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Fulvestrant; Fulvestrant; Letrozole; Megestrol; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 29 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 23 Sep 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top